Epsilogen Completes Acquisition of TigaTx
Deal News | Apr 08, 2025 | EIN
Epsilogen, a leader in IgE antibody therapeutics, has finalized the acquisition of TigaTx, a company specializing in IgA antibodies, positioning itself as the world's pre-eminent pan-isotype cancer antibody entity. By integrating TigaTx, Epsilogen aims to facilitate breakthroughs in oncology by leveraging multiple antibody isotypes - IgE, IgA, and IgG - to address diverse cancer environments and challenges more effectively. This strategic merge also includes a notable addition to Epsilogen's leadership as Dr. Sonia Gulati, from Global BioAccess Fund, joins their board. The acquisition enhances Epsilogen's pipeline, adding TigaTx's EPS 401, which targets the EGFR via IgA, expected to reach clinical trials by 2026. This move supports Epsilogen's mission to create novel cancer treatments that harness the body's immune system by combining the unique properties of different antibody classes, offering innovative therapeutic solutions for cancer patients. Financial details of the transaction were not disclosed.
Sectors
- Biotechnology
- Healthcare
Geography
- United States – TigaTx, a company involved in the acquisition, is based in the US, indicating the relevance of the US market in this context.
- United Kingdom – Epsilogen, the acquiring company, is headquartered here, highlighting the UK's role in this transaction and its biotech industry.
- Netherlands – The article references pioneering work conducted at Utrecht Medical Center, indicating the significance of Dutch contributions to this field.
Industry
- Biotechnology – The article discusses companies involved in the development of therapeutic antibodies for cancer treatment, a key segment of the biotechnology sector.
- Healthcare – The focus on cancer treatment aligns with the healthcare industry, particularly in the development and provision of new therapeutic solutions.
Financials
- Not Disclosed – The financial terms of the acquisition deal between Epsilogen and TigaTx.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Epsilogen | Acquiring Company | Company | Epsilogen is a leader in the development of pan-isotype antibody therapeutics for cancer, specializing in IgE, IgA, and IgG. |
| TigaTx | Target Company | Company | TigaTx is a US-based biotechnology firm focused on engineered IgA antibodies and neutrophil engager therapeutics. |
| Global BioAccess Fund | Investor/Board Member | Company | An entity that has a principal, Dr. Sonia Gulati, joining Epsilogen's board following the acquisition. |
| Epidarex Capital | Investor | Company | Pete Finan, from Epidarex Capital, is Epsilogen’s non-executive chairman, indicating financial backing and strategic insight into the acquisition. |
| Utrecht Medical Center | Research Institution | Company | Location of foundational research for TigaTx’s engineered IgA antibodies, emphasizing academic contributions to the sector. |